Skip to main content
In-Vitro Research Only
Sign in

CJC 1295 Ipamorelin: What the True Data Really Says

Compliance & Laboratory Safety Team4th Sep 2026

CJC 1295 Ipamorelin: What the True Data Really Says
AT A GLANCE · KEY RESEARCH SUMMARY

What You Need to Know About Ipamorelin

Primary Focus
Pituitary growth hormone signalling, tissue remodelling, and synergistic peptide mechanics in laboratory models.
Molecular Profile
CJC-1295 is a 29-amino-acid growth hormone-releasing hormone analogue (3367.97 g/mol without DAC; 3647.28 g/mol with DAC), paired with Ipamorelin, a selective pentapeptide ghrelin mimetic (711.85 g/mol).
Fridge Storage
2°C–8°C (12–24 Months)
Quality Standard
99%+ HPLC Verified
  • Curious readers frequently search for the CJC 1295 Ipamorelin combination to understand how dual-pathway peptides interact to amplify natural growth hormone pulses.
  • CJC-1295 binds to growth hormone-releasing hormone receptors to set a steady baseline signal, while Ipamorelin activates ghrelin receptors to trigger a sharp, immediate release.
  • Published studies in preclinical models demonstrate that combining these two compounds produces a stronger signalling cascade than studying either peptide alone.
  • Laboratory models show that Ipamorelin selectively targets growth hormone release without significantly elevating stress hormones like cortisol or prolactin.

How Dual-Receptor Signalling Drives Cellular Recovery and Rest

In laboratory models, the growth hormone secretagogues CJC-1295 and Ipamorelin work as a complementary pair to amplify natural pulsatile signalling without disrupting baseline hormone rhythms. By binding to two distinct receptor families on pituitary somatotrophs, this combination triggers a cleaner, more pronounced release of endogenous growth hormone and insulin-like growth factor 1 (IGF-1) than either compound achieves alone.

To see why researchers study the cjc 1295 ipamorelin pairing so closely, it helps to look at how the pituitary gland regulates cellular recovery and slow-wave sleep cycles. CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of twenty-nine amino acids. In preclinical models, it binds directly to GHRH receptors, increasing intracellular cyclic adenosine monophosphate (cAMP). This action tells the cells to produce and store more growth hormone, setting a higher ceiling for when a release pulse occurs.

Ipamorelin takes a completely different route. It is a pentapeptide—a tiny chain of five amino acids—that mimics ghrelin by binding to the growth hormone secretagogue receptor (GHS-R1a). Rather than using the cAMP pathway, Ipamorelin activates phospholipase C and mobilises intracellular calcium ions. It also temporarily quiets somatostatin, the hormone that acts as the pituitary gland's natural brake pedal. With the brake lifted by Ipamorelin and the accelerator pressed by CJC-1295, the resulting pulse is notably stronger.

Published studies also highlight what Ipamorelin leaves untouched. Older secretagogues often caused spikes in cortisol, prolactin, and adrenocorticotropic hormone (ACTH), which complicated experimental data on tissue repair and sleep architecture. Ipamorelin shows high selectivity for somatotrophs, meaning measured levels of stress hormones remain stable in animal models. When researchers examine non-DAC CJC-1295 (often called Mod GRF 1-29) alongside Ipamorelin, they observe sharp, natural-looking hormone waves that align with nocturnal recovery phases, protein synthesis, and collagen turnover.

Ipamorelin vial
IN STOCK UK · 99%+ HPLC PURITY · NEXT-DAY DISPATCH

Ipamorelin

From £11

Supplied as a sealed freeze-dried vial (stable 12–24 months at 2°C–8°C in a standard refrigerator).

Shop Ipamorelin →

Tracking the Clock: From Early Pulses to Tissue Remodelling

When scientists track the cjc 1295 ipamorelin combination in preclinical models, the observed outcomes split clearly into immediate biochemical signalling and slower structural adaptation. Nothing in biology changes overnight, and published studies show a distinct progression from the first receptor contact to measurable shifts in tissue composition.

During the first few hours after exposure in laboratory models, the action is purely electrical and chemical. Non-DAC CJC-1295 has a plasma half-life of roughly thirty minutes, while Ipamorelin clears in about two hours. Within twenty to forty minutes of contact, pituitary cells release a sharp pulse of growth hormone into the bloodstream. Over the first seven to fourteen days of repeated pulsatile stimulation, hepatic tissue responds to these waves by steadily raising baseline IGF-1 concentrations. In animal sleep studies, this early window often correlates with changes in slow-wave sleep architecture, as GHRH receptor activity is closely tied to deep rest states.

Between weeks three and six, the consistent elevation in IGF-1 and pulsatile growth hormone begins to alter cellular turnover rates. Fibroblasts and myoblasts in preclinical models show increased amino acid uptake and faster ribonucleic acid (RNA) translation. Researchers monitoring nitrogen balance and lipid oxidation notice that adipose cells start mobilising stored triglycerides more readily, while lean tissue retains nitrogen more efficiently after physical stress.

Structural tissue remodelling takes the longest to appear in published studies, typically requiring eight to twelve weeks of consistent protocol ratios. This is because structural proteins like type I collagen in tendons, dermis, and cartilage have slow natural turnover rates. By the two-to-three-month mark in laboratory models, researchers can measure denser collagen matrix organisation, improved skin elasticity metrics, and stronger bone mineral density readouts. Understanding this timeline helps explain why short-term cellular assays only capture the initial signalling spike, whereas longer observation windows are needed to measure physical recovery.

Research Note: Research Note: In laboratory models, pairing the GHRH analogue CJC-1295 with the selective ghrelin mimetic Ipamorelin amplifies pulsatile growth hormone release while keeping cortisol and prolactin at baseline levels. Always verify whether a study uses CJC-1295 with DAC or Mod GRF 1-29 (without DAC), as the DAC component extends the half-life from thirty minutes to roughly six days.

Biochemical Comparison of CJC-1295 Variants and Ipamorelin in Laboratory Models

CharacteristicCJC-1295 (with DAC)CJC-1295 (without DAC / Mod GRF 1-29)Ipamorelin
Primary Receptor TargetGrowth hormone-releasing hormone receptor (GHRHR)Growth hormone-releasing hormone receptor (GHRHR)Growth hormone secretagogue receptor (GHSR-1a / Ghrelin receptor)
Amino Acid Length30 amino acids (includes lysine linker and maleimidopropionic acid)29 amino acids (tetrasubstituted analogue of native GHRH 1-29)5 amino acids (Aib-His-D-2-Nal-D-Phe-Lys-NH2)
Observed Half-Life in ModelsApproximately 6 to 8 days due to albumin bindingApproximately 30 minutesApproximately 2 hours
Signalling PatternSustained baseline elevation of growth hormone and IGF-1 levelsShort, natural-style pulsatile waveRapid, selective pulse without somatostatin suppression
Off-Target Pituitary ActivityMinimal impact on cortisol or prolactin in published studiesMinimal impact on cortisol or prolactin in published studiesHighly selective; no observed rise in ACTH, cortisol, or prolactin

Smart Pairing: Why These Two Sequences Work Better Together

While the cjc 1295 ipamorelin blend is already a two-part stack, researchers frequently explore how it interacts with other targeted sequences in preclinical models. Because CJC-1295 and Ipamorelin handle systemic anabolic signalling—raising the overall availability of growth hormone and IGF-1—they pair naturally with peptides that focus on local tissue repair or mitochondrial energy.

One of the most common comparisons in laboratory literature involves swapping or comparing Ipamorelin with an older ghrp research peptide such as GHRP-6 or GHRP-2. While GHRP-6 acts on the same ghrelin receptor as Ipamorelin and produces a strong synergistic pulse when combined with CJC-1295, it also strongly stimulates gastric motility and appetite signalling in animal models. Researchers choose Ipamorelin when they want pure somatotroph activation without the ghrelin-driven feeding response, or they select GHRP-6 when studying energy intake alongside tissue growth.

For studies centred on structural recovery—such as tendon, ligament, or muscle remodelling—investigators often examine the CJC-1295 and Ipamorelin pair alongside BPC-157 and TB-500 (Thymosin Beta-4). The logic behind this four-way protocol is straightforward. BPC-157 upregulates growth hormone receptor expression on local fibroblasts and promotes angiogenesis, while TB-500 guides actin polymerisation and cell migration to damaged sites. By adding CJC-1295 and Ipamorelin to the experimental model, those newly upregulated receptors on the fibroblasts receive a richer supply of circulating growth hormone and IGF-1, accelerating extracellular matrix repair.

Another avenue of study combines these secretagogues with GHK-Cu, a naturally occurring copper-binding tripeptide. While CJC-1295 and Ipamorelin support dermal thickness and systemic collagen synthesis from the inside out via IGF-1, GHK-Cu modulates metalloproteinases and stimulates glycosaminoglycan synthesis locally. Together, they allow researchers to observe how systemic endocrine pulses and local gene modulation cooperate during tissue regeneration.

CJC 1295 Ipamorelin: What the True Data Really Says

Figure: CJC 1295 Ipamorelin: What the True Data Really Says

Reconstitution calculator

Choose a vial mass and a bacteriostatic reconstitution solution volume. The figure is the resulting concentration.

Vial mass
Bacteriostatic reconstitution solution

Concentration: 2.50 mg/mL

Per 0.01mL (10µL): 25.0 mcg

Open the full calculatorBacteriostatic reconstitution solution

Inside the Vial: Why HPLC Testing and Cold Storage Matter

Evaluating the true data on cjc 1295 ipamorelin requires looking closely at the physical chemistry inside the research vial. Because this protocol relies on two separate amino acid chains—a twenty-nine-residue sequence and a five-residue sequence—the quality of the solid-phase synthesis directly dictates whether laboratory models produce clean data or muddled results.

Every batch used for reliable study should carry a verified certificate of analysis showing at least ninety-nine percent purity via High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS). During synthesis, incomplete coupling can leave behind truncated peptide fragments. If a vial contains ninety-two percent pure material, the remaining eight percent consists of broken sequences and synthesis byproducts that can bind to receptors without activating them, effectively blocking the intended signalling pulse.

Equally important is the removal of trifluoroacetic acid (TFA). TFA is a strong acid used to cleave peptides from their resin beads during manufacturing. Low-grade vials often retain high levels of residual TFA salts, which lower the pH of the liquid upon mixing and cause cellular irritation or skewed assay readouts in preclinical models. Premium research preparations undergo ion-exchange chromatography to swap harsh TFA ions for benign acetate salts, preserving both cellular health and sequence stability.

Proper storage is the final piece of the puzzle. As a lyophilised (freeze-dried) powder, the blend is stable at minus twenty degrees Celsius for long-term archiving. Once mixed with a bacteriostatic reconstitution solution, the fragile peptide bonds become susceptible to hydrolysis and thermal degradation. The liquid must be stored immediately in a standard refrigerator between two and eight degrees Celsius, kept away from UV light, and swirled gently rather than shaken. Shaking creates shear forces that can denature the secondary folding of the twenty-nine-amino-acid CJC-1295 chain, rendering the solution inactive before an experiment even begins.

Frequently Asked Questions

Why do people search for CJC 1295 Ipamorelin together?

People look up the CJC 1295 Ipamorelin pairing because scientists study how these two synthetic peptides work together to trigger growth hormone signalling in laboratory models. CJC 1295 binds to GHRH receptors, whilst Ipamorelin targets ghrelin receptors, creating a stronger pulse than either compound manages on its own.

What timeline do published studies follow when observing CJC 1295 and Ipamorelin?

Published studies typically track receptor signalling changes over periods ranging from a single twenty-four-hour cycle to twelve weeks in preclinical models. Researchers measure growth hormone pulses within minutes of exposure, whilst downstream changes in IGF-1 levels and tissue remodelling markers are analysed across several weeks of ongoing observation.

Why are CJC 1295 and Ipamorelin combined in laboratory research?

Researchers combine CJC 1295 and Ipamorelin to study dual-pathway synergy in pituitary cells. Because one peptide amplifies the natural release signal and the other suppresses somatostatin—the hormone that stops release—studying them at a set protocol ratio lets scientists characterise maximum receptor output without raising cortisol or prolactin.

How is CJC 1295 Ipamorelin purity verified and stored in the lab?

Laboratory-grade CJC 1295 and Ipamorelin require at least ninety-eight percent purity, verified through High-Performance Liquid Chromatography and Mass Spectrometry testing. Freeze-dried peptide powders remain stable at minus twenty degrees Celsius, whilst samples mixed with bacteriostatic reconstitution solution are kept refrigerated between two and eight degrees Celsius to prevent degradation.

Bibliography

  • Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. View published research
  • Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of preclinical Endocrinology and Metabolism. 2006;91(3):799-805. View published research
  • Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism. 2006;291(6):E1290-E1294. View published research
  • Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-acting GRF analog. Endocrinology. 2005;146(7):3052-3058. View published research
  • Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone and IGF Research. 1999;9(2):106-113. View published research

⚠️ Research Use Only Disclaimer: All peptides and compounds are sold strictly for in-vitro laboratory research purposes only. Not intended for human or veterinary use, not a dietary supplement, and not approved to diagnose, treat, cure, or prevent any disease or condition. For use by qualified researchers in suitably equipped laboratory environments only. Amino Peptides Ltd operates in full compliance with UK MHRA regulations and applicable EU research chemical guidelines.